Biography
Dr. Valery Gmiro is the leading researcher of Institute Experimental Medicine (Russia). He has published more than 100 papers in reputed journals. The main scientific interest concerns the chemistry and pharmacology of biologically active compounds. He is the USSR State Prise Winner for the investigations in the field of physiology of synaptic transmission. During last years V.Gmiro is working on the problem of the creation of adaptogenic drugs acting through activation of afferent nerves. These drugs were shown to be effective tools to study the mechanisms of transmission of afferent signals and may be of interest in clinic using.
Abstract
Porsolt test is a widely used animal model of depression in rats. Amitriptyline is a standard antidepressive drug used in high doses causing strong sedative side effect. Phenylephrine in high dose produced antidepressive effects without side sedative action. The aim of present work was to study the antidepressive and sedative effects of the combination amitriptyline in high and low doses with phenylephrine in threshold noneffective alone doses. Single i. m. injection of amitriptyline in rats in high doses of 10—30 mg/kg causes a weak antidepressive effect because only in 1.3—1.7 times decrease immobilization in Porsolt test. In the specified doses amitriptyline exhibits appreciable sedative effect because in 3—6 times decrease horizontal activity, and also in 2—2.5 times decrease vertical activity of rats in the open field test. Combined single i.m. injection of amitriptyline in a small dose of 3 mg/kg and high dose of 30 mg/kg with phenylephine in threshold, noneffective alone dose of 0.02 mg/kg, causes the maximal antidepressive effect because decreases immobilization in Porsolt test, accordingly, in 3 and 4.6 times, but does not produce side sedative effect in the open field test. The mechanism of potentiation of the antidepressive effect and elimination of the sedative side effect of amitriptyline is based on stimulation of gastric vagal mucosa afferents by phenylephine.
Biography
Sahar Mohamed Kamal Shams El Dine has received her MD in basic and clinical pharmacology from Pharmacology Department, Faculty of Medicine, Ain Shams University during the period of May 1997- May 2001. Currently, she is working as Professor of pharmacology in Ain Shams University. Her research has included CNS and CVS experimental work. She is serving as an Editorial Member of several reputed journals like Journal of Neurological Disorders & Expert Reviewers for journals like Journal of Experimental Pharmacology. She have authored 24 research articles. Her research articles are published on ResearchGate and www.academia.edu.
Abstract
Quetiapine is a novel anti-psychotic drug. However, there is limited clinical evidence regarding prescribing patterns for quetiapine when used as maintenance treatment for bipolar disorder. Thirty-six albino rats were divided into 3 equal groups: control normal group [1] without exposure to chronic restraint for 6 hours daily/21 days, group [2] received DMSO 5% (v:v), as a solvent of quetiapine, with exposure to chronic restraint for 6 hours daily/21 days and group [3] received quetiapine 10 mg/kg/day i.p. for 3 weeks during exposure to chronic restraint for 6 hours daily/21 days. Intraperitoneal (i.p.) administration of quetiapine at a dose of 10 mg/kg/day for 3 weeks significantly (p<0.05) reduces the duration of immobility recorded by the Forced Swimming Test (FST) and significantly (p<0.05) increases the contents of GABA neurotransmitter in hippocampus homogenates. The present study adds a positive implication of quetiapine, as an antipsychotic drug, on both the immobility and the reduction of GABA content in hippocampus of albino rats exposed restraint model for 21 days.